Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/042—Gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/046—Aerosols; Foams
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
  • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/38—Percompounds, e.g. peracids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/731—Cellulose; Quaternized cellulose derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/48—Thickener, Thickening system

Definitions

• the present invention relates to a stable topical aqueous composition of adapalene in combination with benzoyl peroxide comprising one or more gelling agents, wherein at least one of the gelling agents is a carbomer. It also relates to processes for preparing such composition.
• Acne is a disease of the skin in which the pilosebaceous structures of the skin become inflamed, leading to the formation of comedones, pustules, and nodules. It is generally believed that acne arises when hyperkeratosis of the pilosebaceous structure wholly or partially blocks the opening of the structure, resulting in comedones filled with sebum, keratin, and Propionibacterium acnes ("P. acnes"). These lesions are commonly identified as acne. P. acnes naturally occurs in normal skin, but is especially and characteristically present in acne lesions. It is believed that metabolic by-products and waste from P. acnes within the pilosebaceous structures cause or contribute to the inflammation of acne lesions.
• Oral drugs include antibiotics like tetracycline, minocycline, doxycycline, and erythromycin.
• Topical agents for the treatment of acne include retinoids such as tretinoin and adapalene; sulfur; resorcinol; salicylic acid; benzoyl peroxide; and antibiotics such as erythromycin, clindamycin, or tetracycline.
• Antimicrobial resistance to topical therapy is becoming an important factor in the treatment of acne, and clinically an association between the presence of antimicrobial resistant organisms and therapeutic failure has been observed.
• the concomitant administration of two or more anti-acne agents prevents the development of resistant microorganisms, and proves to be more effective in the treatment of acne.
• Epiduo ® topical gel which contains 0.1% of adapalene and 2.5% of benzoyl peroxide.
• Other combination products are Benzamycin ® topical gel, which contains 3% of erythromycin and 5% of benzoyl peroxide, and Benzaclin ® topical gel, which contains 1% of clindamycin phosphate and 5% of benzoyl peroxide. It has been noted that the combination of benzoyl peroxide and retinoids shows synergism in the treatment of acne. Benzoyl peroxide acts by destroying P. acnes, the bacteria that causes the condition acne.
• a further obstacle in formulating the combination is instability of retinoids in the presence of benzoyl peroxide.
• Most retinoids are prone to oxidation, and since benzoyl peroxide is a strong oxidizing agent, the compatibility of these compounds in the same formulation poses numerous problems in terms of physical and chemical stability.
• compositions comprising combinations of benzoyl peroxide and adapalene with particular gelling agents.
• U.S. Patent Nos. 7,820, 186 and 7,964,202; and U.S. Publication Nos. 2008/0176954 and 201 1/0070274 disclose combination formulations formulated with Simulgel ® 600 gelling agent.
• 201 1/0003894 and 2010/0143285 disclose combinations comprising carrageenan gelling agent and polyurethane polymer, respectively.
• U.S. Publication No. 2010/0022642 discloses a gelling system comprising of two categories of compounds selected from silicates, cellulose gelling agents, and polysaccharide gums.
• U.S. Publication Nos. 2009/0318550 and 2010/0166852 disclose many gelling agents including polyacrylamides and polysaccharides, and in particular teach away from the use of carbomers for a combination composition of adapalene and benzoyl peroxide. It is being stated that the use of carbomers in an aqueous composition does not give good results in terms of chemical stability of the benzoyl peroxide or in terms of rheological stability. However, the present inventors have developed a stable topical composition comprising a combination of a retinoid with benzoyl peroxide and a carbomer gelling agent.
• the present invention relates to a stable topical aqueous composition of adapalene in combination with benzoyl peroxide comprising one or more gelling agents, wherein at least one of the gelling agents is a carbomer.
• the present invention relates to a stable topical aqueous composition having a pH of about 4 to about 6.5 comprising:
• the topical aqueous composition of the present invention is in the form of a gel, solution, foam, lotion, or spray. More particularly, the topical aqueous composition of the present invention is in the form of a gel.
• adapalene is present in a concentration from about 0.001% to about 20% by weight of the composition, and benzoyl peroxide is present in a concentration from about 0.001% to about 20% by weight of the composition. More particularly, adapalene is present in a concentration from about 0.01% to about 10% by weight of the composition, and benzoyl peroxide is present in a concentration from about 0.01% to about 20% by weight of the composition.
• the composition comprises a retinoid other than adapalene.
• the retinoid is selected from natural or synthetic retinoids comprising tazarotene, retinoic acid, tretinoin, isotretinoin, bexarotene, alitretinoin, Vitamin A, retinol, retinal, retinyl palmitate, retinyl acetate, (6-((4,4-dimethyl thiochroman-6yl)ethynyl)pydin -3-yl)methanol, 2-(2-(4,4-dimethyl thiochroman-6-yl)-ethynyl)-5-pyridinecarboxaldehyde, ethyl 5-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)thiophene-2-carboxylate, or salts or derivatives thereof.
• the carbomer gelling agent alone or in combination with other gelling agents is present in a concentration of about 0.001% to about 30%, particularly in a concentration of about 0.01% to about 10%, more particularly in a concentration of about 0.1% to about 5% by weight of the composition.
• the composition further comprises a film- forming agent.
• the composition comprises one or more pharmaceutically acceptable excipients selected from the group comprising water-miscible solvents, pro-penetrating agents, preservatives, antioxidants, chelating agents, surfactants - particularly liquid wetting surfactants, sunscreens, humectants, moisturizers, pH-adjusting agents, colorants, fragrances, perfumes, or mixtures thereof.
• pharmaceutically acceptable excipients selected from the group comprising water-miscible solvents, pro-penetrating agents, preservatives, antioxidants, chelating agents, surfactants - particularly liquid wetting surfactants, sunscreens, humectants, moisturizers, pH-adjusting agents, colorants, fragrances, perfumes, or mixtures thereof.
• composition of the present invention comprises an additional anti-acne agent.
• the present invention relates to a method of treating acne by administering a stable topical aqueous composition having a pH of about 4 to about 6.5, comprising:
• the composition comprises the other gelling agents selected from the group comprising cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, and hydroxypropylmethyl cellulose; polyvinylalcohol; natural and synthetic gums such as guar gum, hydroxypropyl guar gum, xanthan gum, acacia, and tragacanth; modified starch; acrylic acid/ethyl aery late copolymers; maleic anhydride-alkyl methylvinylethers and copolymers; polymethacrylate copolymers; oleogels; trihydroxystearin; aluminum magnesium hydroxy stearate;
• cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, and hydroxypropylmethyl cellulose
• polyvinylalcohol such as guar gum, hydroxypropyl guar gum, xanthan gum, aca
• poloxamer polyvinyl alcohol; methyl hydroxybenzoate; ethyl hydroxybenzoate; propyl hydroxybenzoate; butyl hydroxybenzoate; polyacrylamide; or mixtures thereof.
• the present invention relates to a stable topical aqueous composition having a pH of about 4 to about 6.5 comprising:
• the present invention relates to a process for preparing a topical aqueous composition of adapalene and benzoyl peroxide, wherein the process comprises:
• step (a) aqueous phase of step (a) and mixing them to form the drug dispersion;
• step (d) mixing the drug dispersion of step (b) with the gelling agent dispersion of step (c);
• the present invention relates to a process for preparing a topical aqueous composition of adapalene and benzoyl peroxide, wherein the process comprises:
• step (d) adding the benzoyl peroxide dispersion obtained in step (b) to the gelling phase obtained in step (a) under stirring;
• step (e) adding the adapalene dispersion obtained in step (c) to the final material obtained in step (d);
• the present invention provides a stable topical aqueous composition for the treatment of a skin disorder, particularly acne.
• the stable topical composition having a pH of about 4 to about 6.5 comprises a therapeutically effective amount of adapalene, a therapeutically effective amount of benzoyl peroxide, one or more pharmaceutically acceptable excipients, and one or more gelling agents, wherein at least one of the gelling agents is a carbomer.
• terapéuticaally effective amount means that amount of a compound which, when administered to a subject for treating a state, disorder, or condition, or causing an action, is sufficient to effect such treatment, or action.
• the therapeutically effective amount will vary depending on the compound, the disease and its severity, and the age, weight, physical condition, and responsiveness of the mammal to be treated.
• adapalene includes the base as well as salts formed with a
• adapalene salts also includes the salts formed with fatty amines such as dioctylamine and stearylamine.
• the composition of the present invention may comprise a retinoid other than adapalene.
• the retinoid is selected from natural or synthetic retinoids comprising tazarotene, retinoic acid, tretinoin, isotretinoin, bexarotene, alitretinoin, Vitamin A, retinol, retinal, retinyl palmitate, retinyl acetate, (6-((4,4-dimethyl thiochroman-6yl)ethynyl)pydin -3-yl)methanol, 2-(2-(4,4-dimethyl thiochroman-6-yl)-ethynyl)-5-pyridinecarboxaldehyde, ethyl 5-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)thiophene-2-carboxylate, or salts or derivatives thereof.
• the topical aqueous composition of the present invention is present in the form of a gel, solution, foam, lotion, or spray. More particularly, it is in the form of a gel.
• Adapalene is present in a concentration from about 0.001% to about 20% by weight of the composition, and benzoyl peroxide is present in a concentration from about 0.001% to about 20% by weight of the composition. More particularly, adapalene is present in a concentration from about 0.01% to about 10% by weight of the composition, and benzoyl peroxide is present in a concentration from about 0.01% to about 20% by weight of the composition.
• gelling agent is synonymous with viscosifying agent, solidifier, or thickening agent, and refers to an agent that increases the viscosity of the formulation by forming a crosslinking structure.
• the gelling agent used in the present invention is a carbomer or a mixture of a carbomer with other gelling agents.
• carbomers are high molecular weight water-soluble polymers of acrylic acid cross-linked with allyl ethers of sucrose and/or pentaerythritol.
• Carbomers have different viscosities depending on their polymeric composition.
• Examples of carbomers for use herein include various grades of Carbopol ® such as, for example, Carbopol ® 910, 934, 940, 941, 974, 980, 981, 1342, 5984, ETD 2020, ETD 2050, and Ultrez 10.
• the preferred grade is Carbopol ® 980 because it is a highly efficient thickener and it is ideal for formulating clear aqueous and hydroalcoholic gels. Its benefits include short flow properties, high viscosity, high suspending ability, and high clarity.
• gelling agents which may be used in combination with carbomers include cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, and hydroxypropylmethyl cellulose; polyvinylalcohol; natural and synthetic gums such as guar gum, hydroxypropyl guar gum, xanthan gum, acacia, and tragacanth; modified starch; acrylic acid/ethyl acrylate copolymers; maleic anhydride-alkyl methylvinylethers and copolymers; polymethacrylate copolymers; oleogels;
• trihydroxystearin aluminum magnesium hydroxy stearate; poloxamer; polyvinyl alcohol; methyl hydroxybenzoate; ethyl hydroxybenzoate; propyl hydroxybenzoate; butyl hydroxybenzoate; polyacrylamide; or mixtures thereof.
• the gelling agent is present in the composition at a concentration that provides sufficient viscosity to the composition to allow the composition to adhere to the skin for a sufficient period of time to allow the active ingredients to act on the affected areas.
• two or more gelling agents are used in combination.
• the gelling agent is present in a concentration of about 0.001% to about 30%, particularly in a concentration of about 0.01% to about 10%, more particularly in a concentration of about 0.1% to about 5% by weight of the composition.
• the pharmaceutical composition of the present invention can further include one or more film-forming agents.
• film-forming agent means an ionic or non-ionic hydrophilic polymer having a molecular mass at least greater than 10,000, which during application to the skin forms a continuous film.
• film-forming agents include, but are not limited to, hydroxypropylmethylcellulose, ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, cellulose acetate, hydroxypropylmethylcellulose phthalate, cellulose acetate trimellitate, methacrylic acid copolymers such as Eudragit ® , polyvinylpyrrolidone, polyvinylalcohol, polyethylene glycol, or mixtures thereof.
• the pharmaceutical composition of the present invention can further include one or more pharmaceutically acceptable excipients selected from the group comprising water- miscible solvents, pro-penetrating agents, preservatives, antioxidants, chelating agents, surfactants - particularly liquid wetting surfactants, sunscreens, humectants, moisturizers, pH-adjusting agents, colorants, fragrances, perfumes, or mixtures thereof.
• pharmaceutically acceptable excipients selected from the group comprising water- miscible solvents, pro-penetrating agents, preservatives, antioxidants, chelating agents, surfactants - particularly liquid wetting surfactants, sunscreens, humectants, moisturizers, pH-adjusting agents, colorants, fragrances, perfumes, or mixtures thereof.
• Suitable examples of water-miscible solvents include, but are not limited to, water, ethanol, propylene glycol, glycerin, polyethylene glycol, or mixtures thereof.
• compositions of the invention may contain one or more pro-penetrating agents in preferential concentrations ranging from about 0% to about 20% by weight, and more preferably, ranging from about 2% to about 6% by weight, relative to the total weight of the composition. They should generally not dissolve the active agents at the percentage used, should not cause any exothermic reactions harmful to benzoyl peroxide, should aid in the satisfactory dispersion of the active agents, and should have antifoaming properties. Suitable pro-penetrating agents are selected from the group comprising of propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol, or mixtures thereof.
• composition of the present invention may comprise about 0% to about 2.0% by weight of preservatives by total weight of the composition.
• preservatives include, but are not limited to, methyl, ethyl, propyl, and butyl esters of hydroxy benzoic acid, benzoic acid, chlorhexedine, benzalkonium chloride, 2-phenoxyethanol, cetrimide, potassium sorbate, thiomersal, or mixtures thereof.
• antioxidants include, but are not limited to, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium metabisulfite, ascorbic acid, ascorbyl palmitate, thiourea, acetylcysteine, dithiothreitol, cysteine hydrochloride, propyl gallate, tocopherol, or mixtures thereof.
• BHA butylated hydroxyanisole
• BHT butylated hydroxytoluene
• sodium metabisulfite sodium metabisulfite
• ascorbic acid ascorbyl palmitate
• thiourea acetylcysteine
• dithiothreitol cysteine hydrochloride
• cysteine hydrochloride propyl gallate
• tocopherol or mixtures thereof.
• BHT butylated hydroxytoluene
• Antioxidants may be present in an amount of about 0% to about 0.3% by weight of the composition.
• chelating agents include, but are not limited to, edetate salts, for example, edetate disodium and citric acid.
• Chelating agents chelate metal ions present in the composition that may be detrimental to the shelf life of the formulation. Particularly, the chelating agent is present in an amount of about 0.01% to about 0.5% by weight of the composition.
• a surfactant may also be included in the formulation of the present invention to allow good dispersion of the active ingredients.
• surfactants include, but are not limited to, polyethoxylated fatty acid esters, polyoxyethylene sorbitan esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan esters, sodium lauryl sulphate, docusate sodium, nonooxynol, glyceryl monostearate, or mixtures thereof.
• the liquid wetting surfactants used in the present invention include compounds of the poloxamer family, and more particularly poloxamer 124, and poloxamer 182.
• the pharmaceutical composition of the present invention may also include one or more pH-adjusting agents.
• pH-adjusting agents include, but are not limited to, pharmaceutically acceptable organic or inorganic acids or bases, for example, sodium hydroxide, tromethamine, hydrochloric acid, or mixtures thereof.
• the compositions of the present invention have a pH of about 4 to about 6.5.
• humectants include, but are not limited to, glycerol and sorbitol.
• fragrances and perfumes include, but are not limited to, lavender oil, rose oil, lemon oil, and almond oil.
• the present invention relates to a process of preparing a stable topical aqueous composition of adapalene and benzoyl peroxide, wherein the process comprises:
• step (a) aqueous phase of step (a), and mixing them to form the drug dispersion;
• step (d) mixing the drug dispersion of step (b) with the gelling agent dispersion of step (c);
• the present invention also relates to a process of preparing a stable topical aqueous composition of adapalene and benzoyl peroxide, wherein the process comprises:
• step (d) adding the benzoyl peroxide dispersion obtained in step (b) to the gelling phase obtained in step (a) under stirring;
• step (e) adding the adapalene dispersion obtained in step (c) to the final material obtained in step (d);
• the present invention also relates to a method for treating acne by administering the composition of the present invention to an affected area of the subject's skin having such a disorder in an amount and for a period of time sufficient to improve the skin disorder.
• composition of the present invention may further include an additional antiacne agent.
• additional anti-acne agents include, but are not limited to, an antibiotic, salicylic acid, azelaic acid, retinoids other than adapalene, metronidazole, or mixtures thereof.
• Step (c) material was added to step (b) material, and mixed under stirring.
• step (e) Poloxamer 124 was added to step (d) material, and mixed under stirring.
• Adapalene was added to another portion of aqueous phase, and mixed under stirring.
• Step (c) Step (a) material was added to step (b) material and mixed under stirring.
• Carbomer was added to a portion of purified water, and mixed under stirring.
• step (2) The drug dispersion of step (2) was mixed with the gelling agent dispersion of step (3).
• step (3) The pH was checked, and adjusted to 5 ⁇ 0.5 with sodium hydroxide solution.
• Table 1 shows physical properties of the gel composition prepared according to Example 1 after storage under normal and accelerated conditions.
• step (b) Benzoyl peroxide was added to step (a) material, mixed under stirring, and homogenized to get a uniform dispersion.
• Step (2) material was added to step (1) material under stirring.
• Step (3) material was added to step (a) material under stirring.
• Table 2 shows physical properties of the gel composition prepared according to Example 2 after storage under accelerated conditions.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Birds (AREA)
• Dermatology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Emergency Medicine (AREA)
• Dispersion Chemistry (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48142029

Family Applications (1)

Country Status (4)

Cited By (8)

Citations (27)

• 2013
  • 2013-02-21 IN IN497DE2012 patent/IN2012DE00497A/en unknown
  • 2013-02-21 EP EP13717315.9A patent/EP2817069A1/en not_active Withdrawn
  • 2013-02-21 BR BR112014020545A patent/BR112014020545A2/pt not_active IP Right Cessation
  • 2013-02-21 IN IN7896DEN2014 patent/IN2014DN07896A/en unknown
  • 2013-02-21 WO PCT/IB2013/051434 patent/WO2013124820A1/en active Application Filing

Patent Citations (31)

Also Published As

Similar Documents

Legal Events